What caused the pre-market volume spike in BMY.SW stock?

The spike reflects concentrated trades on the SIX listing: **Volume 500 vs Avg 22**. Likely causes are block trades, cross-list flows or positioning ahead of the earnings release on 5 Feb 2026. Low average prints amplify relative volume readings.

Is BMY.SW stock a buy after this drop?

Meyka AI currently grades BMY.SW **B (HOLD)**. The 1‑year model target is **CHF48.40** (+13.76%), but heightened leverage and earnings risk advise waiting for confirmation or buying with strict stops.

How does valuation compare to sector peers for BMY.SW stock?

BMY.SW trades at **P/E 18.26**, below the healthcare sector average **~34.87**. That gap reflects cheaper multiples but higher debt (Debt/Equity **2.92**), so valuation alone is not a quality signal.

Where can I track updates for BMY.SW stock before earnings?

Monitor SIX order prints, the company earnings release on **2026-02-05**, and news feeds. For market context see CNBC and MarketWatch coverage and the Meyka stock page for realtime metrics [Meyka stock page](https://meyka.ai/stocks/BMY.SW).

CH Stocks

BMY.SW down 4.40% to CHF42.54 pre-market SIX 29 Jan 2026: Volume spike

ByDanny Kontos January 29, 2026January 29, 2026

BMY.SW stock fell 4.40% in pre-market trading to CHF42.54 on the SIX exchange on 29 Jan 2026, driven by a sharp volume spike. Volume on the Swiss listing printed 500 versus an average of 22, giving a relative volume of 22.73x, which suggests short-term repositioning ahead of results. Investors should watch the upcoming earnings on 5 Feb 2026 and intra-day liquidity given the wide variance from average volume. We outline valuation, technicals, and a Meyka AI forecast to frame potential trade scenarios.